NeuroNOS
- Biotech or pharma, therapeutic R&D
NeuroNOS may be the first company to normalize neuronal and synaptic morphology and dysfunctions in autism — not just improve symptoms, but reverse damage.
Our nitric oxide–based platform, grounded in discoveries from MIT, Harvard, and Hebrew University, has delivered extraordinary preclinical outcomes:
• Behavioral normalization & brain repair in autism models
• Significant tumor regression and survival gains in glioblastoma
• Memory recovery in Alzheimer’s models
We’re guided by two Nobel Laureates, top U.S. autism trial Clinicians, and have already received FDA Orphan Drug Designation. Manufacturing is underway and 1.5 kg of API is ready.
We’d welcome the opportunity to connect at BIO 2025 to explore potential collaboration or investment. This platform offers a differentiated, mechanism-driven approach to treating some of the most challenging brain disorders.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}